Standpoint Research Starts Kite Pharma (KITE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Standpoint Research Starts Kite Pharma (KITE) at Buy
August 17, 2015 8:00 AM EDT
Kite KTE-C19 Trial on Track to Advance to Pivotal Phase 2
Kite to Host Conference Call and Webcast on August 17, 2015 at 9:00am Eastern Time
SANTA MONICA, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq: KITE) today provided an update from the Company's ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin's lymphoma (NHL) who have failed prior chemotherapy treatments and have a poor prognosis. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to... More
August 17, 2015 8:00 AM EDT
Kite KTE-C19 Trial on Track to Advance to Pivotal Phase 2
Kite to Host Conference Call and Webcast on August 17, 2015 at 9:00am Eastern Time
SANTA MONICA, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq: KITE) today provided an update from the Company's ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin's lymphoma (NHL) who have failed prior chemotherapy treatments and have a poor prognosis. KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to... More
